Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb

No refractures were reported during…

Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogeneic product, in spine fusion

Novadip reports key nonclinical and…

Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a new game changer in the bone field

At six months post-grafting surgery…

Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer

Mont Saint-Guibert, Belgium – December…

Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma

Study results demonstrate NVD-003 has…

Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million

Funding will support development of…

Novadip Biosciences announces EUR 19 million Series B financing backed by international investors

Novadip Biosciences announces EUR 19…

Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion

Novadip Biosciences reports positive data…

Novadip Biosciences receives IND approval from the FDA for regenerative bone product NVD-003

Novadip Biosciences receives IND approval…

Novadip Biosciences, spin-off de l’UCLouvain et les Cliniques universitaires Saint-Luc (UCLouvain) ont réalisé une première mondiale en matière de reconstruction osseuse

Première mondiale dans le domaine…